The FDA has approved Hovilpri for immunocompromised adults with refractory mucocutaneous HSV lesions, offering a novel oral treatment.

Two respiratory syncytial virus (RSV) vaccines, RSVPreF3+AS01 and RSVpreF, were highly effective at preventing hospital admissions and death among older adults during the 2023 to 2024 season. These ...

The M72/AS01 TB vaccine was safe for virologically suppressed adults with HIV, with no severe vaccine-related AEs reported.

Adults hospitalized with CAP face high mortality rates, particularly those with unsuppressed HIV and tuberculosis.

People with HIV experience a significantly greater increase in multimorbidity following COVID-19 diagnosis compared with those without HIV.

An MF59-adjuvanted, higher-dose influenza vaccine improves immune responses in older adults compared with standard egg-based options.

Meningitis incidence and mortality declined significantly in the Western Pacific Region from 1990 to 2023 following expanded vaccination initiatives.

Adults with pneumococcal meningitis of hematogenous origin face a significantly higher 30-day mortality rate than those with other sources.